Terns Pharmaceuticals (TERN) Invested Capital (2020 - 2023)
Historic Invested Capital for Terns Pharmaceuticals (TERN) over the last 4 years, with Q3 2023 value amounting to $258.4 million.
- Terns Pharmaceuticals' Invested Capital rose 4068.23% to $258.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $258.4 million, marking a year-over-year increase of 4068.23%. This contributed to the annual value of $276.9 million for FY2022, which is 7276.22% up from last year.
- According to the latest figures from Q3 2023, Terns Pharmaceuticals' Invested Capital is $258.4 million, which was up 4068.23% from $274.2 million recorded in Q2 2023.
- In the past 5 years, Terns Pharmaceuticals' Invested Capital registered a high of $287.7 million during Q1 2023, and its lowest value of -$119.8 million during Q3 2020.
- Its 4-year average for Invested Capital is $122.5 million, with a median of $172.2 million in 2021.
- Per our database at Business Quant, Terns Pharmaceuticals' Invested Capital soared by 29050.68% in 2021 and then plummeted by 2432.89% in 2022.
- Quarter analysis of 4 years shows Terns Pharmaceuticals' Invested Capital stood at -$104.6 million in 2020, then surged by 253.31% to $160.3 million in 2021, then skyrocketed by 72.76% to $276.9 million in 2022, then dropped by 6.69% to $258.4 million in 2023.
- Its Invested Capital stands at $258.4 million for Q3 2023, versus $274.2 million for Q2 2023 and $287.7 million for Q1 2023.